Parkinson's Disease Expert: "Kainosmed KM-819, Efficacy and Safety Study Results 'Impressive'"

[Asia Economy Reporter Hyunseok Yoo] Dr. Carolyn Ballow, an expert in clinical development of Parkinson's disease treatments, expressed being deeply impressed by the efficacy and safety data of Kainosmed's Parkinson's disease treatment (KM-819).

According to Kainosmed on the 21st, Dr. Carolyn Ballow, former CEO and current board member of the Parkinson's Institute of America (PICC), stated in a recent opinion letter prepared for the preliminary review request to the exchange, "During my tenure as CEO of PICC, I reviewed the preclinical, nonclinical safety data, and Phase 1 clinical data of KM-819."

Dr. Ballow said, "I reviewed data on the efficacy of KM-819 in various preclinical trials, long-term animal toxicity studies, and safety in Phase 1 clinical trials involving humans," adding, "Based on this thorough review, Kainosmed and PICC began collaboration to test the efficacy of KM-819 in animal models that accurately reflect the effectiveness against Parkinson's disease, and advised using cell lines derived from Parkinson's disease patients."

PICC is the only non-profit research institute in the United States specializing in Parkinson's disease, having conducted numerous basic and clinical studies over the past 30 years in addition to treating Parkinson's patients, and currently conducting clinical trials for major drugs under development. PICC possesses know-how in designing clinical trials that can be approved by the U.S. Food and Drug Administration (FDA), based on intellectual property (IP), proprietary patient pathological data, clinical experience, and basic research.

Dr. Ballow stated, "Before serving as CEO of PICC, I worked for several years in the new drug development industry in various executive roles including Chief Medical Officer (CMO) and Chief Scientific Officer (CSO)," and added, "About a year ago, I joined a biotech company as CMO but continue to oversee Kainosmed's clinical co-development activities."

Dr. Ballow joined Kainosmed's Scientific Advisory Board (SAB) last year, advising on the design of the Phase 2 clinical protocol for KM-819 and supporting communication with the FDA.

Meanwhile, Kainosmed recently received approval for a merger listing with Hana Financial No.11 SPAC and is proceeding with the merger process.

This content was produced with the assistance of AI translation services.